Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: DRUG: Olaparib
Sponsor: Hebei Medical University Fourth Hospital